Vericel Corporation VCEL
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +61.79%
- 1 year
- +49.58%
5D -1.11 (-1.88%)
- Market cap
- 2.97B
- Revenue (ttm)
- 324.17M
- Profit margin
- 10.27%
- EPS (ttm)
- 0.64
- Shares out
- 51.03M
- P/E ratio
- 91.03
- Forward P/E
- 61.85
- YTD return
- +61.79%
- 1-year return
- +49.58%
- 50-day average
- 43.90
- Volume
- 686.52K
- Avg volume
- 665.35K
- Open
- 58.74
- Previous close
- 58.65
- Day's range
- 57.72 – 59.66
- 52-week range
- 28.95 – 59.75
- Beta
- 1.06
- Analysts
- Strong Buy
- Price target
- 65.43 (+12.3%)
- Earnings date
- Feb 25, 2027
Key statistics
- 200-day average
- 39.72
- Enterprise value
- 2.91B
- Price / sales
- 9.17
- Price / book
- 7.74
- Revenue growth
- 26.50%
- Free cash flow
- 49.89M
- Total cash
- 170.27M
- Total debt
- 91.15M
- Return on equity
- 9.44%
- Short % of float
- 13.55%
Fundamental scorecard
13 of 25 checks passed on VCEL’s reported financials
13of 25 checks passed
- Value 0 of 5
- Growth 5 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 60.00
- Target (mean)
- 65.43
- Target (high)
- 75.00
- Strong buy0
- Buy7
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.558.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.569 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.05725 | 0.27 | +0.21 | +371.62% |
| Jul 30, 2026 | Jun 30, 2026 | -0.02894 | 0.04 | +0.07 | +238.22% |
| May 7, 2026 | Mar 31, 2026 | -0.15 | -0.12 | +0.03 | +20.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.45 | 0.45 | 0.00 | 0.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.02 | 0.10 | +0.12 | +600.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Stephens & Co. | main | Overweight | Overweight |
| Nov 9, 2026 | Truist Securities | main | Buy | Buy |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 14, 2026 | Truist Securities | main | Buy | Buy |
| Jul 31, 2026 | TD Cowen | main | Buy | Buy |
| Jul 31, 2026 | Truist Securities | reit | Buy | Buy |
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vcel.com
News
Aberdeen Group plc Buys 1,454,012 Shares of Vericel Corporation $VCEL
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026 Stephens & Co. Maintains Overweight on Vericel, Raises Price Target to $68
Truist Securities Maintains Buy on Vericel, Raises Price Target to $65
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $75
Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday
Vericel Q3 2026 Earnings Call Transcript Vericel Q3 EPS $0.27 Beats $0.06 Estimate, Sales $85.371M Beat $77.948M Estimate
Vericel Raises FY2026 Sales Guidance from $330.000M-$340.000M to $344.000M-$346.000M vs $336.224M Est
Your note
Sign in to keep a note on VCEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLANGELO DOMINICK C | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 23, 2026 | 312,446 |
| HAGEN HEIDI M. | Director | Conversion of Exercise of derivative security | Apr 28, 2026 | 35,050 |
| HALPIN MICHAEL | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 2, 2026 | 16,394 |
| HOPPER JONATHAN MARK | Officer | Conversion of Exercise of derivative security | Jun 25, 2026 | 75,753 |
| MARA JOSEPH ANTHONY JR | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 10, 2026 | 16,186 |
| MCLAUGHLIN KEVIN F | Director | Conversion of Exercise of derivative security | Nov 9, 2026 | 18,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.00% | 8,167,305 | 475.83M | Sep 29, 2026 |
| State Street Corporation | 6.28% | 3,202,976 | 186.61M | Sep 29, 2026 |
| Congress Asset Management Co | 5.00% | 2,552,066 | 148.68M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.43% | 2,260,301 | 131.69M | Sep 29, 2026 |
| William Blair Investment Management, LLC | 3.84% | 1,961,248 | 114.26M | Sep 29, 2026 |
| BNP Paribas Asset Management Holding S.A. | 3.21% | 1,640,217 | 95.56M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.97% | 3,047,921 | 177.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 1,617,188 | 94.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 1,328,230 | 77.38M | Sep 29, 2026 |
| Conestoga Funds-Conestoga Small Cap Fund | 2.56% | 1,307,355 | 76.17M | Jun 29, 2026 |
| Professionally Managed Portfolios-Congress Small Cap Growth Fund | 2.28% | 1,165,000 | 67.87M | Oct 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.16% | 1,103,424 | 64.29M | Sep 29, 2026 |
